CSTL · Castle Biosciences, Inc. · Stock research

Current Thesis

The narrative leg is a mix shift: a gastroenterology test (TissueCypher, for Barrett's esophagus) compounding fast enough to overwhelm a dermatology franchise that has stopped growing. On 2026-07-30 Castle reported Q2 2026 revenue of $103.5M against $86.2M in Q2 2025 (+20.1%) and lifted FY2026 revenue guidance to $365–375M from $345–355M — a raise of roughly $20M at the midpoint against a consensus figure of $352.29M per Benzinga's tally. Adjusted EPS came in at $(0.07) versus a $(0.41) estimate. The equity has moved +54.8% over three months into the 2026-08-14 close of $29.62 and still sits 31.2% under the 52-week high of $43.04. What is being bought is the repair of a 2025 de-rating, financed by a product line the market had not underwritten.

Bullish and bearish views on Castle Biosciences, Inc.

The model's bull view on Castle Biosciences, Inc. (CSTL), in brief: Guidance raised on the print, not walked up quietly. The bear view: The legacy derm base is flat to shrinking. Both cases follow in full.

Bull Case

• Guidance raised on the print, not walked up quietly. FY2026 revenue guidance to $365–375M from $345–355M, announced 2026-07-30 alongside a Q2 beat on both lines. Management also guided to positive Adjusted EBITDA in Q3, Q4 and the full year 2026.
• The growth driver is measurable, not thematic. TissueCypher delivered 14,988 test reports in Q2 2026 versus 9,170 in Q2 2025 (+64%). Management framed full-year 2026 TissueCypher volume growth at 50–52% based on first-half trends.
• Operating leverage is showing up. Adjusted EBITDA $12.4M in Q2 2026 versus $10.4M in Q2 2025, on GAAP gross margin of 75% (76% adjusted).
• Balance sheet removes the financing question near-term. Cash and marketable securities of $266.8M at 2026-06-30, against a Q2 GAAP net loss of $2.1M.
• Pipeline has dated milestones, not slideware. AdvanceAD-Tx received New York State Department of Health approval on 2026-07-14 — New York is the one state whose lab approval regime gates commercial launch separately. The DETECT-AD study enrolled its first patient in June 2026.
• Sell-side re-marked upward after the print. BTIG maintained Buy and raised its price target to $44 on 2026-08-03.

Bear Case

• The legacy derm base is flat to shrinking. Q2 2026 report counts: DecisionDx-Melanoma 10,280 (+3% YoY), DecisionDx-SCC 4,011 (−16%), MyPath Melanoma 1,061 (−9%), DecisionDx-UM 482 (+3%). At the Canaccord Genuity Growth Conference on 2026-08-12 management described continued mid-to-high single-digit volume growth for DecisionDx-Melanoma — an improvement on the Q2 print, but not a growth engine.
• DecisionDx-SCC sits outside Medicare coverage following a 2025 coverage change, and the sixteen-percent year-over-year decline in SCC reports is the visible cost. Third-party commentary after the Q2 call points to a CMS update in 2026; no date has been confirmed by the company.
• Concentration migrated rather than resolved. The revenue line now leans on one gastroenterology assay whose adoption curve has never been tested through a reimbursement dispute of the kind DecisionDx-SCC ran into.
• Profitability is adjusted, not GAAP. A $2.1M net loss in Q2 2026 with positive Adjusted EBITDA of $12.4M defines the gap a reader has to be comfortable with.
• The guidance raise was partly ASP-driven, per management's explanation of the raise. Average selling price is a function of payer behaviour and can reverse without any change in volume.

Setup & Price Structure

• Reference close 2026-08-14: $29.62. RSI(14) 69.5. Three-month return +54.8%. Distance from the 52-week high of $43.04: −31.2%.
• Life-cycle: ACCELERATING, dated to the 2026-07-30 beat-and-raise and the 2026-08-03 BTIG target lift to $44. New attention is arriving on fresh numbers; the participation is expanding off a base that was crushed in 2025. The qualifier matters: this is a recovery leg inside an unrepaired drawdown, and the stock has not traded near its 52-week high.
• The August shelf. Shares changed hands at $29.21 on 2026-08-03 (the price on the CCO's Form 4 sale) and closed $29.62 on 2026-08-14 — roughly two weeks of digestion in the same band after the earnings move, without a further leg up.
• Crowding and positioning observables (stated as observables, not verdicts): RSI(14) at 69.5 is in the upper decile of its own range; BTIG's $44 target sits above the $43.04 52-week high, so the published upside requires a full round-trip of the 2025 de-rating; and no earnings date falls inside the next 30 days, so nothing dated forces a repricing in either direction.

Catalyst Calendar (next 30 days)

• 2026-08-15 → 2026-09-14: no confirmed company-dated catalyst. The Canaccord Genuity 46th Annual Growth Conference presentation (2026-08-12) has already taken place. An empty window in an extended name means the tape has to hold the level on flow alone.
• ~2026-11-03 (est.) — Q3 2026 results. Outside the 30-day window. This is where the 50–52% TissueCypher volume growth guide and the $365–375M full-year range get their first real test.
• CMS/MolDX update on DecisionDx-SCC coverage — no confirmed date. Post-call third-party commentary points to an update during 2026. Any reinstatement would restore a line that printed 4,011 reports in Q2 2026 versus 4,762 a year earlier.

What Would Change Our Mind

The leg rests on one number: TissueCypher volume growth. If the Q3 report (est. ~2026-11-03) shows that line running below the guided 50–52% full-year band, the reason the multiple is rebuilding disappears, and a flat DecisionDx-Melanoma franchise plus an uncovered SCC test is what remains. A second break would be an ASP reversal — the FY26 raise was attributed in part to average selling price, so a guidance walk-back framed as payer mix, with volumes intact, would show the raise was not durable.

On price, the gradeable condition is a weekly close below $26, which would put shares beneath the band held since the 2026-07-30 print and mark the post-guidance advance as failed rather than consolidating. A CMS decision that leaves DecisionDx-SCC uncovered, arriving without offsetting TissueCypher acceleration, would compound it. Conversely, a sustained move through $34–$36 on volume with the derm base merely stable would argue the re-rating is broader than a single assay — the theme would then be worth re-reading as MATURING rather than ACCELERATING.

Correlation Notes

• The dominant driver here is inferred, not measured: molecular diagnostics names trade off CMS and MolDX coverage decisions more than off macro. Castle's own 2025 drawdown followed a coverage loss, and its clearest undated upside event is a coverage restoration.
• Peer complex is small/mid-cap molecular diagnostics — Natera, Exact Sciences, Myriad Genetics, Veracyte. Read a coverage or gapfill headline affecting any of them as information about the sector's reimbursement risk premium, not as a Castle-specific datapoint.
• Little linkage to the AI/semiconductor complex. The sensitivity that does exist is to small-cap biotech risk appetite (XBI-type flow) and, through it, to rates: a company running a GAAP net loss with $266.8M of cash carries duration in its valuation.
• Insider transactions here are executed under 10b5-1 plans; a single Form 4 is a scheduling artifact as much as a signal, and only a cluster across multiple officers would carry information.